Better Buy: GW Pharmaceuticals vs. Amarin Two mid-cap biotechs. Two tremendously successful drugs already on the market. But which is the better long-term stock pick? GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats GW Pharmaceuticals (NASDAQ:GWPH) released its preliminary fourth-quarter results for 2019 on Sunday. Sales for the quarter totaled $108 million, with $104 million of that coming from the company's GW Pharmaceuticals has a strong pipeline, AltaCorp says - Cantech Kideckel sees room for meaningful growth for GW Pharmaceuticals,with the company launching several initiatives to help drive and withstand Epidiolex sales GW Pharmaceuticals : 27/10/2015 GW Pharmaceuticals and the
Darüber hinaus umfasst die Pipeline von GW Pharmaceuticals weitere vielversprechende Programme in frühen Phasen. Das Unternehmen evaluiert Cannabidivarin (CBDV), ein weiteres Cannabinoid, das in der Cannabispflanze vorkommt, bei der Behandlung von Epilepsie und Autismus-Spektrum-Störungen. GW erforscht auch den Einsatz von Cannabinoiden bei
Dec 3, 2018 GW Pharma carried out the first controlled clinical trial of CBDV between 2015 and 2017 in patients with inadequately controlled focal seizures. Oct 14, 2019 GW Pharmaceuticals is partnering up with New York's Montefiore Medical Center to study CBDV, or cannabidivarin, as a treatment for autism. Apr 6, 2018 Besides Epidiolex and Sativex, GW Pharmaceuticals continues research and development on cannabidivarin, known as CBDV. Currently
London, UK; 27 April 2015: GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/075,873, a patent application which covers the use of cannabidivarin (CBDV) for treating epilepsy.
CBDv is an promising enough cannabinoid, especially for the treatment of epilepsy, that GW Pharmaceuticals, a British cannabis-centric pharmaceutical company, is in the process of patenting the use of CBDv for the treatment of seizures. Said Justin Gover, GW’s CEO: Cannabidivarin - Wikipedia CBDV has anticonvulsant effects. It was identified for the first time in 1969 by Vollner et al.  Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers ). GW Pharma Phase 2 Trial Using CBDV to Treat Adults with Focal GW Pharma Phase 2 Trial Using CBDV to Treat Adults with Focal Seizures Misses Primary Endpoint . February 21, 2018 at 4:15 pm Published by NCV Newswire GW Pharmaceuticals Announces Preliminary What Is CBDV (Cannabidivarin) And What Does It Do? • High Times
80880e69-fd45-486c-adec-6141cbcbf6c9.pdf October 27, 2015 GW Pharmaceuticals and the Government of New South Wales Announce a Strategic | October 27, 2015
Therapeutic Areas | GW Pharmaceuticals, plc GW’s pipeline in the field of epilepsy currently includes two product candidates: CBD (Epidiolex ® in the US) and GWP42006 (CBDV). Cannabidiol (Epidiolex ® ) GW’s liquid formulation of pure plant-derived cannabidiol (CBD) is being investigated as a treatment for various orphan pediatric epilepsy syndromes. Cannabidivarin - CBDV - Inhaltsstoff - Cannabinoid des Cannabis CBDV wird zur Zeit von der Firma GW Pharmaceuticals untersucht, da es antiepileptisch und krampflösend wirken soll. Cannabinoide mit therapeutischer Wirkung Delta-9-Tetrahydrocannabinol – das vielleicht wichtigste Cannabinoid.